Management tracks: MeiraGTx, Retrophin, Aduro

MeiraGTx Holdings plc (NASDAQ:MGTX) said Katherine Breedis stepped down as CFO on April 16, a little over six months after she joined the gene therapy company. MeiraGTx said COO Richard Giroux will take on the role of CFO.

Retrophin Inc. (NASDAQ:RTRX) said COO Neil McFarlane will depart May 31. The rare disease company did not respond to inquiries regarding plans for a successor.
Aduro Biotech Inc. (NASDAQ:ADRO) hired Dimitry Nuyten as CMO. He was VP and immuno-oncology clinical development leader at Pfizer Inc. (NYSE:PFE). Nuyten joins three months after Aduro announced it would reduce headcount by 37% and prioritize its pipeline to focus on compounds against STING, via its deals with Novartis AG (NYSE:NVS; SIX:NOVN) and Eli Lilly and Co. (NYSE:LLY), and against TNFSF13...